Atinumab Biosimilar - Research Grade

Human

RTN4

>1mg/ml

IgG4 - kappa

CHO Cells

Ozanezumab Biosimilar - Research Grade (ICH5173)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NQC3

Blue ice

Atinumab Biosimilar (Research Grade) is an unconjugated, non-therapeutic research analog of atinumab (originator NG-101), an anti-RTN4/Nogo antibody developed for neurological indications such as spinal cord injury. It is built around the RTN4 (Nogo) target and is supplied as a human IgG4/kappa molecule for research use only; it is not a clinical drug and is not intended for human or animal therapeutic use. Because it reproduces the antigen-binding specificity of the originator, it is well suited as a functional and in-vitro tool for studying RTN4/Nogo biology: target-binding characterization, blockade or neutralization of Nogo-mediated signaling, comparability and reference-standard work, and as a positive control in assay development. The product is offered at low endotoxin (research grade, <1 EU/mg; ultra-low grade <0.5 EU/mg where available) and in bulk milligram-to-gram quantities suitable for scaled and reproducible experimentation. As an IgG4 isotype, it exhibits minimal effector function, consistent with a blocking/neutralizing rather than cell-depleting mechanism. Investigators should confirm suitability for their specific application and validate performance in their own systems. RTN4 (reticulon-4), better known as Nogo, is a member of the reticulon family; UniProt Q9NQC3 corresponds to the Nogo-A (RTN4A) isoform. Reticulon proteins shape the tubular endoplasmic reticulum and contribute to ER membrane curvature and trafficking. Nogo-A is best characterized as a potent myelin-associated inhibitor of neurite outgrowth in the adult central nervous system. Through its Nogo-66 domain and the Nogo-A-specific region, it engages the Nogo receptor (NgR) complex, driving RhoA/ROCK activation, growth-cone collapse, and restriction of axonal regeneration and CNS plasticity. This makes RTN4/Nogo a prominent target for research into spinal cord injury, stroke, and multiple sclerosis, where relieving Nogo-mediated inhibition is hypothesized to promote repair. Isoform expression is enriched in neural tissue, with Nogo-B more broadly distributed.

Foocen, Neurite outgrowth inhibitor, Nogo protein, Neuroendocrine-specific protein, NSP, Neuroendocrine-specific protein C homolog, RTN-x, Reticulon-5, Reticulon-4, NOGO

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks